3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
7
Adenocarcinoma of Lung
5
Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Brain Neoplasms
1
ALK-positive Non-small Cell Lung Cancer
1
ALK-positive NSCLC
1
Interventions
Radiosurgery
27
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Bevacizumab
13
Pemetrexed
10
Carboplatin
10
pembrolizumab
9
Gefitinib
9
osimertinib
8
icotinib
7
Temozolomide
7
Nivolumab
6
Specimen Handling
5
Paclitaxel
5
Spermine Synthase
4
Mental Status and Dementia Tests
4
Ipilimumab
4
Drug Therapy
4
Cisplatin
4
atezolizumab
3
alectinib
3
aflutinib
3
Radiation
3
Immunotherapy
3
Fluorodeoxyglucose F18
3
regorafenib
2
paclitaxel-Angiopep-2 conjugate
2
motexafin gadolinium
2
epothilone B
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
ceritinib
×
Thoracic
×
Clear all
NCT02336451
2020-04-21
Ascend-7
Novartis
Phase 2
Completed
156 enrolled
39 charts